局限性前列腺癌高剂量率近距离治疗单药治疗后尿道狭窄的剂量学与影像组学分析初步研究
回顾性分析178例接受19 Gy单次高剂量率近距离治疗(HDR BT)的局限性前列腺癌患者,中位随访28.2个月,5/178(3%)出现尿道狭窄。匹配配对分析显示狭窄组与对照组尿道剂量学参数无统计学差异(p>0.05),而前列腺MRI影像组学特征中对比度和均匀性在两组间有显著差异(p<0.05),能量特征无差异(p=0.28)。
要点
- HDR BT单药19 Gy治疗后非恶性尿道狭窄发生率为5/178(3%)。
- 尿道剂量学参数与狭窄形成无统计学关联(p>0.05)。
- 前列腺MRI影像组学特征对比度和均匀性在狭窄组与对照组间有显著差异(p<0.05)。
核心结论
- 匹配配对分析未发现治疗后尿道狭窄与尿道剂量学之间的关联。
- 研究产生初步临床假设:前列腺MRI影像组学特征均匀性和对比度可能识别HDR BT后发生狭窄的患者。
- 样本量小,需在更大患者队列中进一步验证。
研究设计与样本
- 回顾性分析2010年11月至2017年7月接受19 Gy单次HDR BT治疗患者的治疗记录。
- 共178例患者接受治疗,中位随访28.2个月,识别5/178(3%)例尿道狭窄。
- 匹配配对分析纳入10例患者,每个狭窄病例按治疗前IPSS评分、使用针数和临床靶区体积匹配一个对照。
- 所有数据集使用治疗前T2加权MRI图像勾画尿道和整个前列腺的兴趣区,选取MRI纹理影像组学特征能量、对比度和均匀性。
- 采用Wilcoxon符号秩检验比较病例与对照的剂量学参数和MRI影像组学特征值。
诊断标准与关键数值
- 尿道狭窄发生频率为5/178(3%),中位随访28.2个月。
- 尿道剂量学参数在狭窄组与对照组间无统计学差异(p>0.05)。
- MRI影像组学特征对比度和均匀性在狭窄组与对照组间有显著差异(p<0.05)。
- MRI影像组学特征能量在狭窄组与对照组间无显著差异(p=0.28)。
临床应用与阅片要点
- 作者认为前列腺MRI影像组学特征均匀性和对比度可能识别HDR BT后易发生狭窄的患者,但样本量小,需进一步验证。
局限性
- 样本量小。
- 研究结果需在更大患者队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: A cohort of high dose-rate (HDR) monotherapy patients was analyzed to (i) establish the frequency of non-malignant urethral stricture; (ii) explore the relation between stricture formation with the dose distribution along the length of the urethra, and MRI radiomics features of the prostate gland.
METHODS: A retrospective review of treatment records of patients who received 19 Gy single fraction of HDR brachytherapy (BT) was carried out. A matched pair analysis used one control for each stricture case matched with pre-treatment International Prostate Symptom Score (IPSS) score, number of needles used and clinical target volume volume for each stricture case identified.For all data sets, pre-treatment T2 weighted MRI images were used to define regions of interests along the urethra and within the whole prostate gland. MRI textural radiomics features-energy, contrast and homogeneity were selected. Wilcoxon signed-rank test was performed to investigate significant differences in dosimetric parameters and MRI radiomics feature values between cases and controls.
RESULTS: From Nov 2010 to July 2017, there were 178 patients treated with HDR BT delivering 19 Gy in a single dose. With a median follow-up of 28.2 months, a total of 5/178 (3%) strictures were identified.10 patients were included in the matched pair analysis. The urethral dosimetric parameters investigated were not statistically different between cases and controls (p > 0.05). With regards to MRI radiomics feature analysis, significant differences were found in contrast and homogeneity between cases and controls (p < 0.05). However, this did not apply to the energy feature (p = 0.28).
CONCLUSION: In this matched pair analysis, no association between post-treatment stricture and urethral dosimetry was identified. Our study generated a preliminary clinical hypothesis suggesting that the MRI radiomics features of homogeneity and contrast of the prostate gland can potentially identify patients who develop strictures after HDR BT. Although the sample size is small, this warrants further validation in a larger patient cohort.
ADVANCES IN KNOWLEDGE: Urethral stricture has been reported as a specific late effect with prostate HDR brachytherapy. Our study reported a relatively low stricture rate of 3% and no association between post-treatment stricture and urethral dosimetry was identified. MRI radiomics features can potentially identify patients who are more prone to develop strictures.
引用
- Tsang YM, Vignarajah D, Mcwilliam A, et al. A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. Br J Radiol. 2019. PMID: 31778319. doi:10.1259/bjr.20190760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。